Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bath & Body Works Inc (BBWI) vs Revvity Inc (RVTY) Price & Performance

Bath & Body Works IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Bath & Body Works Inc vs Revvity Inc — how do they compare? Bath & Body Works Inc trades at $18.52 (market cap $3.81B), while Revvity Inc trades at $115.28 (market cap $12.91B). The key difference: Revvity Inc is far larger — about 3.4× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays the higher dividend (4.24%). Which is the better fit depends on your goals.

BBWIRVTY
Market Cap
$3.81B$12.91B
Sector
Consumer CyclicalTechnology
52-Week High
$31.87$117.75
52-Week Low
$14.85$82.26
Enterprise Value
$7.70B$15.23B
Dividend Yield
4.24%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bath & Body Works Inc

BBWI trades at $19.32, down 5.11% over 24 hours, with a bearish technical signal and key support at $19. The stock shows attractive valuation metrics, including a P/E of 5.36 and P/S of 0.54, with a net income margin of 10.03% for 2025. Recent developments include expansion into Brazil and a partnership with Ulta Beauty, while Q2 2026 earnings are anticipated on August 26, 2026.

The outlook presents a value opportunity given low valuations and strategic growth initiatives, but risks include declining revenue trends, high debt levels, and negative shareholder equity. Analyst consensus is mixed with a $22.11 price target, suggesting potential upside if turnaround efforts succeed amidst competitive and execution challenges.

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Returns comparison

Trailing returns across standard periods

About Bath & Body Works Inc

Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.

Read more on BBWI

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY